Please use this identifier to cite or link to this item: https://doi.org/10.1177/0091270011407195
Title: Semagacestat pharmacokinetics are not significantly affected by formulation, food, or time of dosing in healthy participants
Authors: Willis, B.A.
Zhang, W.
Ayan-Oshodi, M.
Lowe, S.L. 
Annes, W.F.
Sirois, P.J.
Friedrich, S.
De La Peña, A.
Keywords: γ-secretase
Alzheimer disease
Semagacestat
Issue Date: Jun-2012
Citation: Willis, B.A., Zhang, W., Ayan-Oshodi, M., Lowe, S.L., Annes, W.F., Sirois, P.J., Friedrich, S., De La Peña, A. (2012-06). Semagacestat pharmacokinetics are not significantly affected by formulation, food, or time of dosing in healthy participants. Journal of Clinical Pharmacology 52 (6) : 904-913. ScholarBank@NUS Repository. https://doi.org/10.1177/0091270011407195
Abstract: Semagacestat, γ-secretase inhibitor, reduces formation of amyloid beta peptide. Two single-dose (140 mg), openlabel, randomized, 3-period, crossover studies evaluated the effect of formulation, food, and time of dosing on the pharmacokinetics and pharmacodynamics of semagacestat in healthy participants. The first study (n = 14) compared tablet to capsules. For all formulations, the median time to maximum plasma concentration (tmax) was generally 1.0 hour. Plasma elimination was rapid, with a half-life of approximately 2.5 hours. Tablet form II bioavailability (F) relative to capsule was approximately 100% (F = 1.03 [90% confidence interval (CI), 0.96-1.10]). In the second study, participants (n = 27) received semagacestat either fed or fasting in the morning or fasting in the evening. No significant change in exposure (AUC0-8 [area under the concentration-time curve from 0 to infinity] ratio = 1.02, [90% CI, 0.990-1.05]) occurred with food, whereas maximum plasma concentration (Cmax) declined approximately 15%, and median tmax was delayed to 1.5 hours. Time of dosing made no significant difference in AUC0-8, Cmax, or tmax (AUC0-8 ratio 1.01, [90% CI, 0.975-1.04]). No clinically significant safety concerns occurred in either study. Accordingly, semagacestat may be dosed without regard to formulation, food, or time of administration. © 2012 The Author(s).
Source Title: Journal of Clinical Pharmacology
URI: http://scholarbank.nus.edu.sg/handle/10635/112067
ISSN: 00912700
DOI: 10.1177/0091270011407195
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

5
checked on Jun 19, 2018

WEB OF SCIENCETM
Citations

4
checked on Jun 19, 2018

Page view(s)

49
checked on Jun 1, 2018

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.